The 21st Century Business Herald reporter found that the innovative development of the pharmaceutical industry has been mentioned many times according to public data. For example, Zhaochao, deputy to the National People's Congress and President of Buchang pharmaceutical, believes that the current pharmaceutical pattern is changing, especially the scientific innovation driven by clinical value and scientific value, which has gradually become the main driving force for the development of the industry.

In addition, other hot issues were also discussed, such as children's drug safety, public hospital reform, hierarchical diagnosis and treatment, generic drug consistency evaluation and drug bidding and procurement.

Fengdanlong, member of the National Committee of the Chinese people's Political Consultative Conference and director of Pfizer's China enterprise affairs department, said that safety is the top priority for children's medication. However, at present, there are some problems in children's medication, such as unknown clinical medication ingredients and excessive doses. It is necessary to establish and improve children's medication laws and regulations and popularize the knowledge of children's safe medication.

Voice for innovation

Pharmaceutical innovation involves many aspects, such as public drug demand, drug quality and efficacy, and structural reform of drug supply side, and its importance is self-evident.

For example, Ding lieming, deputy to the National People's Congress and chairman of Beida pharmaceutical, pointed out that since 2015, the State Food and Drug Administration (CFDA) has carried out drastic reforms to address the slow pace of drug review and approval, further deepened the reform of the drug review and approval system, and encouraged innovative drug research and development.

On October 8th, 2017, the general office of the CPC Central Committee and the general office of the State Council jointly issued the opinions on deepening the reform of the review and approval system and encouraging innovation in pharmaceutical and medical devices, which greatly stimulated the vitality of pharmaceutical research and development and promoted the industrial structure adjustment and technological innovation of pharmaceutical and medical devices.

Among the representatives and members of the NPC and CPPCC sessions, there are also many innovative enterprises, such as Cheng Jing, President of Boao bio Group Co., Ltd., zhuzhaoyun, R&D director of Yunnan Baiyao Group Co., Ltd., who were elected as deputies to the NPC, and yushengchen, President of yuekang Pharmaceutical Group Co., Ltd., who were elected as members of the CPPCC National Committee.

However, there are still difficulties to be overcome in the development of innovative drugs. To this end, representatives and members of the NPC and CPPCC have made suggestions and suggestions.

For example, Ding lieming pointed out to the reporter of the 21st Century Business Herald that there are still many difficulties in the market access after the R&D and listing of innovative drugs, including drug bidding, secondary price negotiation, hospital drug proportion control, which seriously hinder the clinical application of innovative drugs and affect the accessibility of innovative drugs. He hoped that the relevant ministries and commissions would speed up the reform of the market access mechanism of innovative drugs and overcome the difficulties in the market access of innovative drugs.

"At present, the state has liberalized the pricing power of drugs (except for psychotropic drugs and narcotic drugs), and drug manufacturers have the independent pricing power of drug prices. At the same time, the products entered the medical insurance catalog in all provinces are purchased and settled at 'medical insurance price'." Ding lieming suggested that after the innovative drugs were approved to be listed, they can be directly purchased online, without the need for centralized bidding, quotation and price negotiation, so as to bring benefits to the people as soon as possible.

Sun Feiyang, deputy to the National People's Congress and chairman of Hengrui pharmaceutical, suggested that we should continue to optimize the review and approval process for the listing of new drugs, gradually change the current trend of checking every time, realize the synchronization of on-site inspection of production and on-site inspection of clinical trials, and issue specific procedures and requirements for rolling submission of data.

"At this stage, the development of the pharmaceutical industry is very fast. It is difficult to carry out relevant work without the support of the National Key Laboratory, which is very important to promote the development of the entire pharmaceutical industry." yuebingfei, member of the National Committee of the Chinese people's Political Consultative Conference and researcher of the China Institute for food and drug control, gave suggestions on the construction of the National Key Laboratory.

It is worth noting that in the drug classification, traditional Chinese medicine as a national medicine, its innovation and development has received high attention.

"Innovation is one of the ways out for traditional Chinese medicine. Many traditional Chinese medicines have their material basis. On this basis, the discovery of effective parts and effective ingredients for innovation has become an independent innovative medicine of the Chinese nation. We should develop drugs that can be truly developed into innovative drugs, so that traditional Chinese medicine can realize real modernization." Hu Jiqiang, deputy to the National People's Congress and chairman of conbay, suggested.

Zhao Chao said that the innovation, development and internationalization of traditional Chinese medicine can not be separated from the support of the government. The internationalization of traditional Chinese medicine depends on the support of leading enterprises of traditional Chinese medicine. The modernization and internationalization of traditional Chinese medicine need the support of large varieties. He hoped that the government would increase its support for leading enterprises, create high-quality products with science and technology, and build an aircraft carrier for traditional Chinese medicine enterprises.

Medication safety for children

Innovation is an important starting point to meet the needs of the public for medication, and safety is the top priority in the public's demand for medication. In children, due to the immature development of various organs and other reasons, the drug safety is more concerned.

Fengdanlong believes that children, as a special group, have immature organs. Compared with adults, the usage and dosage of drugs have special requirements. Children are not miniaturized versions of adults.

However, according to statistics, in 2016, children aged 0-14 accounted for 16.6% of the total population in China, and the number of sick children accounted for more than 20% of the total number of sick people. As a special group of drug consumption, the types of children's drugs account for less than 10% of the total amount of drugs. Among the more than 3500 kinds of chemical preparations in China, the proportion for children is less than 2%, and children's special drugs are seriously scarce.

At present, due to the lack of special drugs for children, the vast majority of children can only take adult drugs according to a certain proportion. The use of adult drugs, dosage "by guessing" and tablets "by breaking" is a true portrayal of children's medication in China.

But "relying on guessing" and "relying on breaking" are not conducive to ensuring the safety of medication for children. "Compared with adults, children are not only small and light in weight. The essential difference between the two is that many organ functions of children's body are not well developed, the detoxification and excretion functions of liver and kidney and the role of blood-brain barrier are not perfect, the requirements for the adaptability of drugs are more stringent, the requirements for the safety of drugs are higher, and irrational drug use and medication errors will cause drug-induced damage, or even more serious." xiongweizheng, deputy to the National People's Congress and chairman of Henan Lingrui Group Co., Ltd., pointed out.

In addition, according to the statistics of the white paper of the 2016 children's drug safety investigation report, the adverse drug reaction rate of children in China is 12.5%, twice that of adults, and that of newborns is four times that of adults.

In order to solve the problems existing in children's medication, fengdanlong believed that the National Children's adverse drug reaction monitoring center should be established to analyze and study children's adverse reaction data, realize data sharing nationwide, timely feed back information and change the instructions.

Ding lieming believes that the lack of legislation on drug use for children is also an important reason for the above problems. In China's two most important drug regulations, the drug administration law of the people's Republic of China and the measures for the administration of drug registration, there are no special provisions on children's drugs. "To solve the shortage of special drugs for children, realize the standardized management of drug use, ensure the safety of drug use, and even provide timely intervention and relief for children injured by drugs, it needs to be regulated and guaranteed through national legislation."

In addition, according to the data of the China Pharmaceutical Industry Information Center, there are more than 8000 pharmaceutical manufacturing enterprises nationwide, of which only 0.1% are specialized in the production of children's drugs. In the drug clinical trial registration project, the domestic drug registration information reached more than 160000, including only more than 2000 children's drugs.

Ding lieming pointed out that due to the high cost of research and development of children's drugs and the difficulty of clinical trials, many pharmaceutical companies have no enthusiasm. "For example, the physical development of children at different stages is inconsistent, and the absorption, distribution and metabolism of drugs are different, so it is difficult to obtain accurate research data, and the vast majority of parents are unwilling to take their children as clinical subjects."

To this end, Ding lieming told the 21st Century Business Herald that he hoped that the state would increase its support for the development of children's drugs and establish an incentive mechanism for the development and production of children's drugs.

The 21st Century Business Herald reporter noted that on May 21, 2014, six departments, including the national health and Family Planning Commission and CFDA, jointly issued several opinions on guaranteeing the use of drugs for children, which gave support to the production of children's drugs: policy support was given to the price of drugs for children, and the special dosage forms for children could be listed as a single representative product, which was not affected by the pricing level of adult drugs; Give play to the guarantee function of medical insurance for children's medication, and timely include appropriate dosage forms and specifications for children into the payment scope of basic medical insurance according to regulations.

Focus on medical pain points

In addition to drugs, the government work report focused on the field of medical services, and proposed to strengthen the construction of the general practitioner team, promote hierarchical diagnosis and treatment, and promote "Internet+" in medical treatment, pension, education and other fields.

Maxiuzhen, member of the National Committee of the Chinese people's Political Consultative Conference and director of the health and Family Planning Commission of Ningxia Hui Autonomous Region, pointed out that although the difficulty and high cost of seeing a doctor have been effectively alleviated, the contradiction between the people's new demand for health care and the unbalanced and inadequate supply of medical services has not been completely eliminated. The difficulty and high cost of medical treatment have also been considered as the pain points of current medical treatment,

Hierarchical diagnosis and treatment, as an important measure to rationally allocate medical resources and promote the equalization of medical and health services, is highly expected.

As early as September 11th, 2015, the general office of the State Council issued the guidance on promoting the construction of the hierarchical diagnosis and treatment system. However, there are still difficulties to be solved. For example, maxiuzhen pointed out that medical data and information among departments and medical institutions have not yet been fully shared. It is necessary to promote the interconnection and integrated application of medical professional data, department management data, service agency business data and Internet data, break data barriers and promote value multiplication.

Ma Huateng, deputy to the National People's Congress and chairman of Tencent's board of directors, also believes that we should accelerate the application of digital technology and promote the balanced development of medical resources and capabilities.

As an important step to promote hierarchical diagnosis and treatment, the cultivation of family doctors has also attracted much attention.

Zhengjianjiang, deputy to the National People's Congress and chairman of Oakes group, believes that the number and structure of family doctors in China are unreasonable, and supporting policies and resources are not in place. "The contracted services of family doctors should have provided diagnosis and treatment services for common diseases and frequently occurring diseases, and given priority to the key groups including the elderly and children. However, due to the restrictions of relevant regulations, most primary medical institutions can not see or see the flu."

To this end, zhengjianjiang suggested that the marketization of family doctors' contract signing could be piloted, and social capital such as independent doctors, private clinics and private hospitals could be considered to enter, so as to activate the motivation of family doctors by market competition mechanism; Focus on improving the professionalism and structure of the signing team. The team should have pediatricians and rehabilitation hygienists to provide targeted, personalized and high-quality services to the signing population, especially the key population.

Jiang Ming, deputy to the National People's Congress and chairman of Tianming group, also made suggestions: through the government's full open authorization, guide social forces to participate in family doctor signing services; Guide social capital to provide supporting environment for family doctors in commercial insurance, drug distribution, mobile application development and operation, and improve service capacity.

In addition, yuanyafei, member of the National Committee of the Chinese people's Political Consultative Conference and chairman of sanbo group, paid attention to the issue of the combination of medical care and nursing care.

"In 2017, China's population aged 60 and over was about 241million, including more than 40million disabled and semi disabled elderly. They have been suffering from diseases for a long time, but due to the increasingly small family size, the traditional family pension function is gradually weakening, and the general family is difficult to cope with the pressure of long-term care, so these elderly people especially need government assistance and social care." yuanyafei pointed out.

In Yuan Yafei's view, the long-term care insurance system is the most important institutional guarantee to fundamentally solve the source of nursing funds for the elderly; In addition, home care is the preferred way for the elderly in China, accounting for up to 90%. Home care can enable the disabled and semi disabled elderly to enjoy professional medical care services at home and reduce the nursing burden of their families. "The long-term care insurance will also provide a strong guarantee for the promotion of home care services. Therefore, it is suggested that the government encourage the cooperation between the long-term care insurance and home-based care institutions, and provide support in terms of subsidies, tax incentives, personnel training, etc."